Refill @joinrefill

@hubermanlab 3rd party testing AND prescribed by a physician

@thechadwickpaul My segment won’t build!

We’re not building another LifeFile. And we’re not just helping practices get more affordable meds. We’re simplifying every touchpoint in the prescribing process — testing, learning, and building with providers to make modern prescribing actually feel seamless. More to come.

@PeptideList Retatrutide looks like it could be a game changer. But with something this powerful, medical oversight matters. Better weight loss, liver benefits, labs, side effects, dosing, contraindications — this is not a DIY drug.

The vitamin comparison is actually underselling it. Vitamins fill nutritional gaps. Personalized peptide protocols will work at a completely different level — modulating how your brain functions, how your body repairs itself, how aggressively you age. We're moving from "don't get sick" medicine to "optimize how you live" medicine. That shift is bigger than any single drug. It's a whole new relationship with healthcare.

@theliverdoc The credibility gap is wild. We need educated providers who share clinical evidence that these treatments actually work

The gray market just lost its biggest player. Here's what that means for your practice.

@austinxwalker Thank you! Too many great practices are held back by fragmented pharmacy access and compliance chaos. We're fixing that!

@DrSamuelBHume YES! GLP-1s as a backbone therapy. Everything else — muscle preservation, deeper weight loss, cardiovascular protection — gets added on top. The Ozempic era was chapter one. We're about to read a much longer book.

BPC-157, CJC-1295, Thymosin Alpha-1 — eventually returning to legal compounding status. The pathway: physician prescription → licensed 503A pharmacy → patient-specific preparation. That's it. No gray market. No "research use only" disclaimers. Just compliant care. That's what Refill is built for.

@maxmarchione Fair point. And yet somehow in 2023 the FDA banned BPC-157 because there wasn't enough data. Insulin had zero clinical trials in 1922. The revolution isn't new, but the regulatory whiplash sure is.

@TechWith_Nova Openclaw

Providers are on the front lines delivering care. We're the infrastructure behind the scenes making it work smoothly.Refill supports responsible practices prescribing: • GLP-1s • Peptides • Hormone therapy Zero clinical opinions—just reliable ops, workflows, and compliance tools. On this account, expect: • Practical workflow tips • Key compliance updates • What's shifting in the industry • Real requirements for modern prescribing systems Building responsibly? Stick around—we've got your back. #GLP1 #HormoneTherapy #Peptides #MedSpas #Telehealth